Emerald Mutual Fund Advisers Trust Increases Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Emerald Mutual Fund Advisers Trust lifted its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 19.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 262,571 shares of the company's stock after purchasing an additional 43,296 shares during the period. TransMedics Group comprises 1.3% of Emerald Mutual Fund Advisers Trust's portfolio, making the stock its 27th largest holding. Emerald Mutual Fund Advisers Trust owned approximately 0.78% of TransMedics Group worth $17,666,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TMDX. Nisa Investment Advisors LLC grew its stake in TransMedics Group by 1.6% during the first quarter. Nisa Investment Advisors LLC now owns 15,824 shares of the company's stock valued at $1,065,000 after acquiring an additional 256 shares in the last quarter. OneDigital Investment Advisors LLC grew its stake in TransMedics Group by 52.6% during the first quarter. OneDigital Investment Advisors LLC now owns 5,989 shares of the company's stock valued at $403,000 after acquiring an additional 2,065 shares in the last quarter. D.A. Davidson & CO. grew its stake in TransMedics Group by 12.6% during the first quarter. D.A. Davidson & CO. now owns 12,924 shares of the company's stock valued at $870,000 after acquiring an additional 1,442 shares in the last quarter. Principal Financial Group Inc. lifted its position in TransMedics Group by 2.8% during the first quarter. Principal Financial Group Inc. now owns 198,427 shares of the company's stock valued at $13,350,000 after purchasing an additional 5,480 shares during the last quarter. Finally, Teacher Retirement System of Texas bought a new position in TransMedics Group during the first quarter valued at $330,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Edward M. Basile sold 5,000 shares of the company's stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total value of $632,250.00. Following the sale, the director directly owned 2,866 shares of the company's stock, valued at $362,405.70. This represents a 63.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Anil P. Ranganath sold 686 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the completion of the sale, the insider directly owned 13,955 shares in the company, valued at $1,950,909. This trade represents a 4.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 12,418 shares of company stock valued at $1,512,613. Insiders own 7.00% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on TMDX shares. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 17th. Canaccord Genuity Group lifted their price objective on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a report on Tuesday. Piper Sandler reiterated an "overweight" rating and set a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Finally, Oppenheimer raised their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research report on Tuesday, June 17th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, TransMedics Group currently has a consensus rating of "Moderate Buy" and an average price target of $131.56.

TransMedics Group Stock Down 1.0%

Shares of TransMedics Group stock traded down $1.20 on Tuesday, reaching $115.68. The stock had a trading volume of 740,605 shares, compared to its average volume of 1,375,875. The company has a 50 day moving average price of $125.98 and a 200 day moving average price of $91.24. The company has a quick ratio of 8.32, a current ratio of 9.10 and a debt-to-equity ratio of 1.92. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The stock has a market capitalization of $3.91 billion, a P/E ratio of 85.06 and a beta of 2.06.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.29 by $0.41. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The firm had revenue of $143.54 million for the quarter, compared to the consensus estimate of $123.39 million. During the same quarter in the previous year, the firm earned $0.35 EPS. The company's quarterly revenue was up 48.2% compared to the same quarter last year. As a group, equities research analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.